IFNG and COVID-19: From 8-10 to 14-16 weeks, the proportion of positive severe patients was maintained at approximately 80%, while the proportion of positive mild patients declined from 66.7% to 28.6%, indicating that IFNγ-secreting SARS-CoV-2-specific T cells gradually disappear in mild COVID-19 patients (Figures 6B, D).